C1orf162

Across TCGA pan-cancer cohorts, C1orf162 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C1orf162 data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher C1orf162 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C1orf162 expression acts as an unfavorable survival marker.

SARC, LUSC, and SKCM are the cancer types where C1orf162 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
LUSC	DFS	Median	II,III,IV	0.135	0.663	.015	6	view →
SKCM	DFS	Median	All	0.192	0.757	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

C1orf162–SARC (DFS)

Open the SARC breakdown →